Abstract

After immunohistochemistry (IHC) [1] [2] and the molecular diagnostic revolution [3, 4], Digital Pathology (DP) and Artificial Intelligence (AI) represent an incipient “third revolution” in pathology. DP/AI have the potential to make the complex and fragmented pathway of routine pathological tissue interrogation a more seamless endeavour at, at least, 3 levels, namely a) the analysis of H&E for diagnostic purposes; b) the scoring of tissue hybridization-based biomarkers for therapeutic decision-making; and c) the annotation of H&E samples ahead of nucleic acid extraction. This lecture will discuss in detail our contributions to the application of DP in this areas and, in particular a) the application of QuPath, developed in our laboratory, to the analysis of known biomarkers [5]; b) the analysis of markers of adaptive immunity and cancer immunotherapy [6]; and c) the development and utilization of DP and AI to annotate and characterize the H&E of samples ahead of genomic testing [6]. References1. John Wiley & Sons, Incorporated, ISBN-10 0470032200 & ISBN-13 97804700322062. J Clin Pathol. 2013 Jan;66(1):58-613. Br J Cancer. 2017 Nov 21;117(11):1581-1582. 4. J Clin Pathol. 2018 Apr;71(4):285-290.5. Lab Invest. 2018 Jan;98(1):15-26. 6. Sci Rep. 2017 Dec 4;7(1):16878.